|
|
|
2022, Volume 38, Number 1, Page(s) 009-015
|
|
|
DOI: 10.5146/tjpath.2021.01538 |
Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions |
Monalisa HUI1, Shantveer G UPPIN1, K Karun KUMAR1, S RADHIKA2, P CHANDRASEKHAR3, K Nageshwara RAO3 |
1Department of Pathology, Nizam’s Institute of Medical Sciences, HYDERABAD, INDIA
2Department of Clinical Pharmacology and Therapeutics, Nizam’s Institute of Medical Sciences, HYDERABAD, INDIA
3Department of Orthopaedics, Nizam’s Institute of Medical Sciences, HYDERABAD, INDIA |
Keywords:
Giant cell tumor of bone, Giant cell-containing lesions of bone, p63, Immunohistochemistry |
Objective: To assess P63 expression in giant cell-containing lesions of the bone (GCLB) and to determine its utility in differentiating giant cell
tumor of the bone (GCTB) from other GCLBs.
Material and Method: Cases diagnosed as GCLB on histopathology were included in the study. P63 immunohistochemistry was performed in
all the cases. The percentage of cells showing nuclear positivity was assessed in the non-giant cell component. Statistical analysis was performed
using the Mann-Whitney U test.
Results: Of the total 53 cases studied, the majority were GCTBs (23), followed by 12 cases of chondroblastomas (CBL) and 18 other giant cell
lesions (GCLs). All giant cell-containing lesions except one case of CBL and brown tumor of hyperparathyroidism (BTH) showed P63 staining
in the non-giant cell component. However, the mean P63 labeling of GCT (52.6%) was higher compared to CBL (28.3%), aneurysmal bone cyst
(ABC) (15.2%), non-ossifying fibroma (NOF) (24.5%), giant cell lesion of small bones (GCLSB) (11%), BTH (6.8%) and chondromyxoid fibroma
(CMF) (12.3%), with a p-value of <0.001.
Conclusion: Although p63 was present in majority of the GCLBs, its percentage positivity was significantly higher in GCTB compared to the
other GCLBs. The diagnosis of GCTB is likely if cut-off value of >50% is applied.
|
|
|
|
|
